Skip to main content

DiaSorin S.p.A. (DIA.MI)

MIL Healthcare Medical - Diagnostics & ResearchView data quality →
51.9Fair

ValueMarkers Composite Index

Top 41%#26,492 of 44,707
Undervalued

34% below intrinsic value ($109)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-3.11
Low Risk
Altman
2.38
Grey Zone
DCF Value
$109
Undervalued
ROIC
12.6%
Adequate
P/E
17.6
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

DiaSorin S.p.A. (DIA.MI) — VMCI valuation read

DiaSorin S.p.A. (DIA.MI) carries a VMCI composite of 52/100, 2 points above the Healthcare sector median of 50. Among mid-cap names, that gap places DIA.MI in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The DIA.MI insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads DIA.MI trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.4x leaves covenant headroom, the line to track on DiaSorin S.p.A.'s next 10-Q.

DIA.MI fell 1.9% over the trailing 7 days, with a +2.4% read on a 30-day basis.

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

CEO: Carlo Rosa3,249 employeesITdiasoringroup.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in DIA.MI’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.